SGRY

AI Memo

Surgery Partners

As of 2026-10-10/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-10 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Debt reduction after completed Idaho Falls sale • 2026-12-31

Base target: $16 / p=50% prob

Biggest risk

Q2 case growth was just 0.3%, adjusted EBITDA fell to $125.2 million from $129.0 million, and operating cash flow fell to $59.3 million from $81.3 million. Sale proceeds alone may not resolve operating weakness. No reliable post-sale analyst revisions were supplied. [#SEC-8K-2026-08-10]

Invalidation

Break below $11 or thesis failure.

What would change my mind?

The completed sale creates a specific deleveraging opportunity. If proceeds materially reduce debt while ambulatory case growth and cash conversion improve, the continuing business could merit a higher valuation. [#8-K-2026-09-17] [#SEC-8K-2026-08-10]

Research note

Recommendation

—

Confidence

medium

As of

2026-10-10

Base target

$16

p=50%

Bull target

$19

p=25%

Bear target

$11

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-sale outlook clarification
Case growth and cash conversion
The completed sale creates a specific deleveraging opportunity.

BearKey bullets

Q2 adjusted EBITDA and operating cash flow declined year over year.
[#SEC-8K-2026-08-10]
Q2 revenue-per-case growth substantially exceeded case growth, leaving procedure-volume durability uncertain.

WatchKey bullets

Debt reduction after completed Idaho Falls sale

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $16 (p=50%)

Target spread vs base: +21% / -32%

Scenario probabilities

Bull Target: $19 (p=25%)Base Target: $16 (p=50%)Bear Target: $11 (p=25%)

Commentary

The sale supports a cautiously positive monitoring view, but the supplied anchor does not establish a verified post-sale price reaction. News coverage is thin; analyst revisions, options skew, short interest, employee sentiment, and sufficient social readings were unavailable. Zero sentiment fields mean unavailable data, not neutral measurements. The September 23 StockStory article is third-party opinion, not a company release. [#8-K-2026-09-17] [#SEC-8K-2026-08-10]

As of 2026-10-10 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-sale outlook clarification
Case growth and cash conversion

Scenarios

Bull Target (Scenario probability)

$19 / p=25% prob

Base Target (Scenario probability)

$16 / p=50% prob

Bear Target (Scenario probability)

$11 / p=25% prob

Analysis 2026-10-10 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Debt reduction after completed Idaho Falls sale
The Idaho Falls hospital disposition closed September 14 for approximately $796.6 million, subject to adjustments. Management intends to use the proceeds primarily to repay debt. The next test is actual repayment and resulting leverage; December 31 is an assessment horizon, not an announced milestone. [#8-K-2026-09-17]
Prob 75.00% • Move 9.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

Post-sale outlook clarification
2026-12-31
Q2 guidance of $3.35–$3.45 billion in 2026 revenue and at least $530 million in adjusted EBITDA excluded the then-pending divestiture. A post-sale outlook and reported debt balance would clarify the continuing business; December 31 is a monitoring horizon, not a confirmed report date. [#SEC-8K-2026-08-10] [#8-K-2026-09-17]
Prob 55% • Move 11% • Priced-in 50%

Long-term Catalysts

Months to a year

Case growth and cash conversion
2027-09-30
Q2 same-facility revenue grew 5.0%, largely through 4.8% higher revenue per case; cases rose only 0.3%. Adjusted EBITDA and operating cash flow declined year over year. Sustained case growth and better cash conversion would strengthen the thesis; the date is an assessment horizon. [#SEC-8K-2026-08-10]
Prob 50% • Move 18% • Priced-in 40%

Risks

Q2 adjusted EBITDA and operating cash flow declined year over year. [#SEC-8K-2026-08-10]
Q2 revenue-per-case growth substantially exceeded case growth, leaving procedure-volume durability uncertain. [#SEC-8K-2026-08-10]
Reaffirmed 2026 guidance excluded the divested business; applying it unchanged to the post-sale company would be misleading. [#SEC-8K-2026-08-10]
The $796.6 million sale consideration remains subject to closing and post-closing adjustments; the amount and timing of debt repayment are not yet established. [#8-K-2026-09-17]

Peers

Symbol	Summary
HCA	Hospital and ambulatory operator useful for procedure-volume context, but its much larger scale and broader hospital mix limit valuation comparability.
THC	Its USPI ambulatory business offers an operating comparison, while Tenet's other businesses limit whole-company multiple comparisons.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-10

Loading AI feed…

Symbol

Summary

HCA

Hospital and ambulatory operator useful for procedure-volume context, but its much larger scale and broader hospital mix limit valuation comparability.

THC

Its USPI ambulatory business offers an operating comparison, while Tenet's other businesses limit whole-company multiple comparisons.